Detalhe da pesquisa
1.
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Invest New Drugs
; 35(5): 556-565, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28516360
2.
Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Biol Pharm Bull
; 36(12): 1921-7, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24432379
3.
Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab.
J Pharmacol Exp Ther
; 343(1): 178-83, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22787117
4.
Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model.
Oncotarget
; 13: 1359-1368, 2022 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36537913
5.
Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.
Cancer Sci
; 102(3): 614-21, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21205082
6.
[Pharmacological and clinical profile of gilteritinib (Xospata® tablets 40â mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia].
Nihon Yakurigaku Zasshi
; 156(1): 37-46, 2021.
Artigo
em Japonês
| MEDLINE | ID: mdl-33390479
7.
Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Leuk Res
; 88: 106286, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31865062
8.
Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade.
Sci Transl Med
; 12(526)2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31941828
9.
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
Cancer Res
; 67(17): 8014-21, 2007 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17804712
10.
Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia.
Oncotarget
; 10(26): 2530-2545, 2019 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31069015
11.
Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells.
Oncotarget
; 10(58): 6111-6123, 2019 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31692922
12.
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Mol Cancer Ther
; 18(8): 1366-1373, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31092564
13.
YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Int J Oncol
; 32(3): 545-55, 2008 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-18292931
14.
Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain models.
Eur J Pharmacol
; 589(1-3): 98-101, 2008 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-18565509
15.
Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Clin Cancer Res
; 20(7): 1814-22, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24486595
16.
The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mol Cancer Ther
; 13(2): 329-40, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24419060
17.
Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma.
Leuk Res
; 37(9): 1156-61, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23746965
18.
Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Bone
; 55(1): 189-97, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23486179
19.
Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma.
Leuk Res
; 35(6): 787-92, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21237508
20.
Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.
Nihon Yakurigaku Zasshi
; 134(3): 149-57, 2009 09.
Artigo
em Japonês
| MEDLINE | ID: mdl-19749488